



**Date: October 16, 2024**

**BSE Limited**  
P J Towers,  
Dalal Street,  
Mumbai – 400 001

**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

**Script Code: 543904**

**Symbol: MANKIND**

Dear Sir/ Madam,

**Subject: Allotment of Non-Convertible Debentures**

---

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in continuation to our letter dated September 30, 2024, the Fund Raising Committee of the Directors of the Company vide circular resolution passed today i.e. October 16, 2024, has allotted the following Non-Convertible Debentures;

1. 125,000 INR denominated, listed, rated, secured, redeemable, transferable non-convertible debentures having a face value of INR 100,000 each, aggregating up to INR 12,500,000,000 (NCD Series 1);
2. 125,000 INR denominated, listed, rated, secured, redeemable, transferable non-convertible debentures having a face value of INR 100,000 each, aggregating up to INR 12,500,000,000 (NCD Series 2); and
3. 250,000 INR denominated, listed, rated, secured, redeemable, transferable non-convertible debentures having a face value of INR 100,000 each, aggregating up to INR 25,000,000,000 (NCD Series 3).

The detailed disclosures in respect of NCDs is enclosed as Annexure I.

You are requested to kindly take the above information on your records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

**Pradeep Chugh**  
**Company Secretary and Compliance Officer**

---

**MANKIND PHARMA LIMITED**

Regd. Office : 208, Okhla Ind. Estate, Phase - 3, New Delhi-110020 • Ph. : 011-46846700, 47476600  
CIN No. L74899DL1991 PLC044843 • E-mail : [contact@mankindpharma.com](mailto:contact@mankindpharma.com) • [www.mankindpharma.com](http://www.mankindpharma.com)

Restricted - External

**Annexure I**

Sr. No.	Particulars	NCD Series 1	NCD Series 2	NCD Series 3																														
1.	Type of securities proposed to be issued	Rated, Listed, Secured, Transferable, Redeemable, Non-Convertible Debentures (“NCDs”)																																
2.	Type of issuance	Private Placement																																
3.	Total number of securities proposed to be issued or the total amount for which the securities will be issued	Total number of securities: 125,000 NCDs  Nominal value: INR 100,000 each,	Total number of securities: 125,000 NCDs  Nominal value: INR 100,000 each,	Total number of securities: 250,000 NCDs  Nominal value: INR 100,000 each,																														
4	Size of the issue	Total Size of the issue: INR 12,500,000,000 (Rupees One Thousand Two Hundred Fifty Crores)  Subscription Amount Received: INR 12,52,36,25,000	Total Size of the issue: INR 12,500,000,000 (Rupees One Thousand Two Hundred Fifty Crores)  Subscription Amount Received: INR 12,55,01,24,000	Total Size of the issue: INR 25,000,000,000 (Rupees Two Thousand Five Hundred Crores)  Subscription Amount Received: INR 25,09,68,80,000																														
5	Whether proposed to be listed? If yes, name of the stock exchange(s);	BSE Limited																																
6	Tenure of the instrument - date of allotment and date of maturity	Tenure of Instrument: upto 18 months  Date of allotment: 16/10/2024  Final Date of maturity: 16/04/2026	Tenure of Instrument: upto 24 months  Date of allotment: 16/10/2024  Final Date of maturity: 16/10/2026	Tenure of Instrument: upto 37 months  Date of allotment: 16/10/2024  Final Date of maturity: 16/11/2027																														
7	Coupon/interest offered, schedule of payment of coupon/interest and principal;	Coupon Rate offered: 7.99% per annum payable semi annually  <table border="1"> <thead> <tr> <th>Cash Flows</th> <th>Date at which redemption becoming due</th> </tr> </thead> <tbody> <tr> <td>1<sup>st</sup> Coupon</td> <td>16.4.2025</td> </tr> <tr> <td>2<sup>nd</sup> Coupon</td> <td>16.10.2025</td> </tr> <tr> <td>3<sup>rd</sup> Coupon</td> <td>16.4.2026</td> </tr> <tr> <td>Principal</td> <td>16.4.2026</td> </tr> </tbody> </table>	Cash Flows	Date at which redemption becoming due	1 <sup>st</sup> Coupon	16.4.2025	2 <sup>nd</sup> Coupon	16.10.2025	3 <sup>rd</sup> Coupon	16.4.2026	Principal	16.4.2026	Coupon Rate offered: 7.99% per annum payable semi annually  <table border="1"> <thead> <tr> <th>Cash Flows</th> <th>Date at which redemption becoming due</th> </tr> </thead> <tbody> <tr> <td>1<sup>st</sup> Coupon</td> <td>16.4.2025</td> </tr> <tr> <td>2<sup>nd</sup> Coupon</td> <td>16.10.2025</td> </tr> <tr> <td>3<sup>rd</sup> Coupon</td> <td>16.4.2026</td> </tr> <tr> <td>4<sup>th</sup> Coupon</td> <td>16.10.2026</td> </tr> </tbody> </table>	Cash Flows	Date at which redemption becoming due	1 <sup>st</sup> Coupon	16.4.2025	2 <sup>nd</sup> Coupon	16.10.2025	3 <sup>rd</sup> Coupon	16.4.2026	4 <sup>th</sup> Coupon	16.10.2026	Coupon Rate offered: 7.97% per annum payable semi annually  <table border="1"> <thead> <tr> <th>Cash Flows</th> <th>Date at which redemption becoming due</th> </tr> </thead> <tbody> <tr> <td>1<sup>st</sup> Coupon</td> <td>16.4.2025</td> </tr> <tr> <td>2<sup>nd</sup> Coupon</td> <td>16.10.2025</td> </tr> <tr> <td>3<sup>rd</sup> Coupon</td> <td>16.4.2026</td> </tr> <tr> <td>4<sup>th</sup> Coupon</td> <td>16.10.2026</td> </tr> </tbody> </table>	Cash Flows	Date at which redemption becoming due	1 <sup>st</sup> Coupon	16.4.2025	2 <sup>nd</sup> Coupon	16.10.2025	3 <sup>rd</sup> Coupon	16.4.2026	4 <sup>th</sup> Coupon	16.10.2026
Cash Flows	Date at which redemption becoming due																																	
1 <sup>st</sup> Coupon	16.4.2025																																	
2 <sup>nd</sup> Coupon	16.10.2025																																	
3 <sup>rd</sup> Coupon	16.4.2026																																	
Principal	16.4.2026																																	
Cash Flows	Date at which redemption becoming due																																	
1 <sup>st</sup> Coupon	16.4.2025																																	
2 <sup>nd</sup> Coupon	16.10.2025																																	
3 <sup>rd</sup> Coupon	16.4.2026																																	
4 <sup>th</sup> Coupon	16.10.2026																																	
Cash Flows	Date at which redemption becoming due																																	
1 <sup>st</sup> Coupon	16.4.2025																																	
2 <sup>nd</sup> Coupon	16.10.2025																																	
3 <sup>rd</sup> Coupon	16.4.2026																																	
4 <sup>th</sup> Coupon	16.10.2026																																	

**MANKIND PHARMA LIMITED**

Regd. Office : 208, Okhla Ind. Estate, Phase - 3, New Delhi-110020 • Ph. : 011-46846700, 47476600  
CIN No. L74899DL1991 PLC044843 • E-mail : contact@mankindpharma.com • www.mankindpharma.com

Restricted - External



			3 <sup>rd</sup> Coupon	16.4.2026	5 <sup>th</sup> Coupon	16.4.2027
			4 <sup>th</sup> Coupon	16.10.2026	6 <sup>th</sup> Coupon	16.10.2027
			Principal	16.10.2026	7 <sup>th</sup> Coupon	16.11.2027
				6	Principal	16.11.2027
8	Charge/security, if any, created over the assets	A. Exclusive charge over the designated accounts of the Company and the collection account where, <i>inter alia</i> , issue proceeds of the NCDs are parked pending payment to the Sellers for the Acquisition. B. Pari-passu charge over movable assets (excluding current assets, bank accounts and receivables), present and future, including intellectual property of the Company and pledge over investments of the Company in its subsidiaries and group entities; C. Pari-passu mortgage over identified immovable assets of the Company; and D. Once the acquisition is completed, the NCDs will also be secured by exclusive pledge of shares and securities of Bharat Serums and Vaccines Limited to be acquired by the Company.				
9	Special right/interest/privileges attached to the instrument and changes thereof;	As set out in the relevant debenture trust deeds ("DTDs") executed between the Company and the common debenture trustee, and any other related document thereto.				
10	Delay in payment of interest / principal amount for a period of more than three months from the due date or default in payment of interest / principal	Not Applicable				
11	Details of any letter or comments regarding payment/non-payment of interest, principal on due dates, or any other matter concerning the security and /or the assets along with its comments thereon, if any;	Not Applicable				

**MANKIND PHARMA LIMITED**

Regd. Office : 208, Okhla Ind. Estate, Phase - 3, New Delhi-110020 • Ph. : 011-46846700, 47476600  
CIN No. L74899DL1991 PLC044843 • E-mail : [contact@mankindpharma.com](mailto:contact@mankindpharma.com) • [www.mankindpharma.com](http://www.mankindpharma.com)

Restricted - External